Wednesday, November 4, 2026
Two papers, a psychopharmacology pearl, a psychotherapy pearl and the news.
AI-generated content. This briefing was written by Claude Opus 5.5 and may contain errors. Please verify against the primary source before acting clinically.
| The Paper |
| New research from the psychiatric journals |
Prefrontal Cortical Changes With Mindfulness-Oriented Recovery Enhancement in Opioid Use Disorder: A Randomized Clinical Trial
Huang Y, Ceceli AO, Kronberg G, et al.; Garland EL, Goldstein RZ. JAMA Psychiatry. October 2026.
Adults with opioid use disorder recruited from an inpatient rehabilitation facility in New York were randomized to eight weekly 2-hour groups of Mindfulness-Oriented Recovery Enhancement (MORE: mindfulness, reappraisal of drug cues, and deliberate savoring of natural rewards) or an active control of psychoeducational supportive therapy. The primary outcome was change on fMRI; 59 participants had usable drug-cue imaging.
Compared with the control group, MORE reduced drug-biased activity in the middle frontal gyrus and precuneus when participants tried to turn down their response to drug cues and turn up their response to natural reward cues. In the MORE group only, a shift from drug toward natural-reward responding in lateral and ventromedial prefrontal cortex tracked with lower cue-induced craving. MORE also extended abstinence duration at roughly four months after treatment, although the effect was small (Cohen w = 0.19) and follow-up data were available for only 38 people.
|
In practice
This is a small mechanistic trial, not a definitive outcomes study, but it gives a biological rationale for adding a skills-based group that retrains reward valuation alongside buprenorphine or methadone. Medication handles withdrawal and overdose risk; something still has to make ordinary pleasures worth more than the drug. |
Full text doi:10.1001/jamapsychiatry.2026.3388
| Outside Psychiatry |
| A general-medicine paper that ends up in our clinic |
Preoperative Intranasal Oxytocin and Probable Acute Stress Disorder After Traumatic Fracture Surgery: A Randomized Clinical Trial
Huang Q, Wen Y, Li Q, et al.; Shu H. JAMA Internal Medicine. October 2026.
In a single-center double-blind trial in China, 328 adults scheduled for surgery after a traumatic fracture were randomized to a single dose of intranasal oxytocin 40 IU or saline placebo, given 10 minutes before anesthesia induction. The primary outcome was screening-positive probable acute stress disorder (Stanford Acute Stress Reaction Questionnaire score of 40 or more) within three days of surgery.
Probable acute stress disorder occurred in 15.9% of the oxytocin group versus 30.5% with placebo, a risk difference of 14.6 percentage points (risk ratio 0.52). Exploratory resilience, anxiety and depression scores and salivary stress biomarkers moved in the same direction, and there were no serious adverse events. The outcome was a screening threshold at three days, not a clinician-diagnosed disorder, and there was no long-term follow-up for PTSD.
|
In practice
Trauma surgery is one of the most common routes into PTSD that psychiatry rarely sees early. This is a single-center trial built on a screening endpoint, so it does not justify routine use, but it is a reason to screen orthopedic trauma patients for acute stress symptoms on the consult service rather than waiting for PTSD to show up months later. |
Full text doi:10.1001/jamainternmed.2026.5326
| Past the Boards |
| One advanced clinical point, usually pharmacology |
Cariprazine's slowest metabolite decides when you'll see the dose you chose
Cariprazine itself has a half-life of 2 to 4 days, but its major active metabolite, didesmethyl-cariprazine (DDCAR), has a half-life of one to three weeks and comes to dominate total exposure at steady state. So a dose change on cariprazine is only fully expressed several weeks later. The label says to monitor for adverse effects and response for several weeks after starting and after every dose increase.
This matters most for akathisia. It can first appear in week three or four of an unchanged dose, after you've stopped expecting it, and look like new anxiety or worsening agitation. Moving the dose up before the last increase has reached steady state stacks exposure you haven't seen yet. The same tail works in your favor after a missed dose or an abrupt stop: active drug remains for weeks, which softens nonadherence but also means side effects resolve slowly. Both parent and metabolites go through CYP3A4: halve the dose when a strong 3A4 inhibitor is added, and avoid the drug with strong inducers like carbamazepine or rifampin.
| In the Room |
| A psychotherapy technique, shown in a vignette |
Ask for associations to a dream before you offer it a meaning
When a patient brings a dream, the trainee's pull is to decode the symbols, often with an interpretation that happens to fit the session's working theme. Doing this skips the part of the dream that belongs to the patient. Freud's technical rule still holds: the meaning lives in the patient's associations, not in the images. Take the dream one element at a time and ask what comes to mind. Start with the day residue, what happened in the day or two before that the dream borrowed. Then notice which element the patient hurries past or tells flatly, because the affect is often displaced away from what matters. A dream told early in treatment, or right after a break, frequently carries the transference in disguise. The therapist may show up as a minor figure: a doctor, a ticket agent, someone who arrives late. Interpreting from your own associations rather than the patient's tells them their mind is less interesting than your theory.
|
Vignette
A man in his 40s, three weeks after the therapist's vacation, reports a dream: he is at an airport gate, the flight is delayed, and an attendant at the counter is polite but won't tell him when it will board. He tells it as a joke about bad airlines. The resident is tempted to name abandonment outright. Instead she asks, "What comes to mind about the attendant?" He says she was pleasant, "the kind of person who's paid to be nice to you." Asked about being delayed, he recalls his father regularly arriving hours late to custody pickups. Only then does she offer a link: "Someone pleasant, paid to be kind, who controls when things resume. I wonder if that's how my vacation felt." He goes quiet, then says he almost cancelled today. Waiting for his associations is what gave the interpretation its weight. |
| Elsewhere |
| Developments worth knowing about |
| • | New York Gov. Kathy Hochul signed S9051B on October 28, 2026. Starting January 1, 2027, chatbot companies may not offer minors features such as bots that pretend to be human or that encourage self-harm, and must verify users' ages. Ask adolescent patients which AI companions they use and what those bots say to them. (source) |
| • | The UK MHRA's October 15, 2026 Drug Safety Update adds a boxed warning and a patient card to antidepressant leaflets covering suicidal thoughts and sexual dysfunction that may persist after stopping ("PSSD"). Patients will arrive having read it, so cover both risks at initiation and at each dose change. (source) |
| *** |
| That's the five. Go see your first patient. |